[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA Cancer J Clin,2021,71(3):209-249.
[2] SHAPIRO J,VANLANSCHOT JJB,HULSHOF MCCM,et al.Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS):long-term results of a randomised controlled trial ［J］.Lancet Oncol,2015,16(9):1090-1098.
[3] OPPEDIJK V,VAN DER GAAST A,VAN LANSCHOT JJ,et al.Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials ［J］.J Clin Oncol,2014,32(5):385-391.
[4] AJANI JA,D'AMICO TA,BENTREM DJ,et al.Esophageal and esophagogastric junction cancers,version 2.2019,NCCN clinical practice guidelines in oncology ［J］.J Natl Compr Canc Netw,2019,17(7):855-883.
[5]WANG H,TANG H,FANG Y,et al.Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma:a randomized clinical trial ［J］.JAMA Surgery Vol,2021,156(5):444-451.
[6] WATANABE M,OTAKE R,KOZUKI R,et al.Recent progress in multidisciplinary treatment for patients with esophageal cancer［J］.Surg Today,2020,50(1):12-20.
[7] VON DOBELN GA,KLEVEBRO F,JACOBSEN AB,et al.Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction:long-term results of a randomized clinical trial［J］.Dis Esophagus,2019,32(2):10.
[8] YANG H,LIU H,CHEN Y,et al.Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma:the NEOCRTEC5010 randomized clinical trial［J］.JAMA Surg,2021,156(8):721-729.
[9] SOHDA M,KUWANO H.Current status and future prospects for esophageal cancer treatment［J］.Ann Thorac Cardiovasc Surg,2017,23(1):1-11.
[10] VAN DER WILK BJ,EYCK BM,LAGARDE SM,et al.The optimal neoadjuvant treatment of locally advanced esophageal cancer ［J］.J Thorac Dis,2019,11(Suppl 5):S621-S631.
[11] ALDERSON D,CUNNINGHAM D,NANKIVELL M,et al.Neoadjuvant cisplatin and fluorouracil versus epirubicin,cisplatin,and capecitabine followed by resection in patients with oesophageal adenocarcinoma(UK MRC OE05):an open-label,randomised phase 3 trial［J］.Lancet Oncol,2017,18(9):1249-1260.
[12] YCHOU M,BOIGE V,PIGNON JP,et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and FFCD multicenter phase III trial［J］.J Clin Oncol,2011,29(13):1715-1721.
[13] CUNNINGHAM D,ALLUM WH,STENNING SP,et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer［J］.N Engl J Med,2006,355(1):11-20.
[14] ANDO N,KATO H,IGAKI H,et al.A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus(JCOG9907)［J］.Ann Surg Oncol,2012,19(1):68-74.
[15] ALLUM WH,STENNING SP,BANCEWICZ J,et al.Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer［J］.J Clin Oncol,2009,27(30):5062-5067.
[16]］ KELSEN DP,WINTER KA,GUNDERSON LL,et al.Long-term results of RTOG trial 8911(USA Intergroup 113):a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer ［J］.J Clin Oncol,2007,25(24):3719-3725.
[17]SUGIMURA K,YAMASAKI M,YASUDA T,et al.Long-term results of a randomized controlled trial comparing neoadjuvant adriamycin,cisplatin,and 5-fluorouracil vs docetaxel,cisplatin,and 5-fluorouracil followed by surgery for esophageal cancer(OGSG1003)［J］.Ann Gastroenterol Surg,2020,5(1):75-82.
[18] AKIYAMA Y,SASAKI A,ENDO F,et al.Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer:a retrospective cohort analysis ［J］.World J Surg Oncol,2018,16(1):122.
[19] AL-BATRAN SE,HOMANN N,PAULIGK C,et al.Perioperative chemotherapy with fluorouracil plus leucovorin,oxaliplatin,and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced,resectable gastric or gastro-oesophageal junction adenocarcinoma(FLOT4):a randomised,phase 2/3 trial ［J］.Lancet,2019,393(10184):1948-1957.
[20] ONITILO AA,STANKOWSKI-DRENGLER TJ,SHIYANBOLA O,et al.Modified docetaxel,cisplatin,and fluorouracil(mDCF) as a neoadjuvant chemotherapy for non-metastatic esophageal cancer(nMEC)［J］.Clin Med Res,2021,19(2):64-71.
[21] OJIMA T,NAKAMORI M,NAKAMURA M,et al.Neoadjuvant chemotherapy with divided-dose docetaxel,cisplatin and fluorouracil for patients with squamous cell carcinoma of the esophagus ［J］.Anticancer Res,2016,36(2):829-834.
[22] FITENI F,PAGET-BAILLY S,MESSAGER M,et al.Docetaxel,cisplatin,and 5-fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma ［J］.Cancer Med,2016,5(11):3085-3093.
[23] FAN Y,JIANG Y,ZHOU X,et al.Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma ［J］.Oncotarget,2016,7(31):50624-50634.
[24] KANDA M,KOIKE M,IWATA N,et al.An open-label single-arm phase II study of treatment with neoadjuvant S-1 plus cisplatin for clinical stage III squamous cell carcinoma of the esophagus ［J］.Oncologist,2020,25(11):e1650-e1654.
[25] UEDA H,KAWAKAMI H,NONAGASE Y,et al.Phase II trial of 5-fluorouracil,docetaxel,and nedaplatin(UDON)combination therapy for recurrent or metastatic esophageal cancer ［J］.Oncologist,2019,24(2):163-e76.
[26] SATO Y,MOTOYAMA S,WADA Y,et al.Neoadjuvant chemoradiotherapy followed by esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma patients with clinical stage III and with supraclavicular lymph node metastasis［J］.Cancers(Basel),2021,13(5):983.
[27] VAN HAGEN P,HULSHOF MC,VAN LANSCHOT JJ,et al.Preoperative chemoradiotherapy for esophageal or junctional cancer ［J］.N Engl J Med,2012,366(22):2074-2084.
[28] YANG H,LIU H,CHEN Y,et al.Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus(NEOCRTEC5010):aphase III multicenter,randomized,open-label clinical trial ［J］.J Clin Oncol,2018,36(27):2796-2803.
[29] SEMENKOVICH TR,SAMSON PP,HUDSON JL,et al.Induction radiation therapy for esophageal cancer:does dose affect outcomes［J］.Ann Thorac Surg,2019,107(3):903-911.
[30] BUCKSTEIN M.Optimal radiation dose in the neoadjuvant management of esophageal cancer ［J］.J Thorac Dis,2020,12(8):4568-4570.
[31] MARIETTE C,DAHAN L,MORNEX F,et al.Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer:final analysis of randomized controlled phase III trial FFCD 9901 ［J］.J Clin Oncol,2014,32(23):2416-2422.
[32] YOON HH,OU FS,SOORI GS,et al.Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma:a multicentrerandomised phase II trial(NCCTG N0849 ［Alliance］)［J］.Eur J Cancer,2021,150:214-223.
[33] RENEHAN AG,MALCOMSON L,EMSLEY R,et al.Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer(the OnCoRe project):a propensity-score matched cohort analysis ［J］.Lancet Oncol,2016,17(2):174-183.
[34] MEHANNA H,WONG WL,MCCONKEY CC,et al.PET-CT surveillance versus neck dissection in advanced head and neck cancer ［J］.N Engl J Med,2016,374(15):1444-1454.
[35] PARK SR,YOON DH,KIM JH,et al.A randomized phase III trial on the role of esophagectomy in complete responders to preoperative chemoradiotherapy for esophageal squamous cell carcinoma(ESOPRESSO)［J］.Anticancer Res,2019,39(9):5123-5133.
[36] JIA R,YIN W,LI S,et al.Chemoradiation versus oesophagectomy for locally advanced oesophageal cancer in Chinese patients:study protocol for a randomised controlled trial ［J］.Trials,2019,20(1):206.
[37] VAN DER WILK BJ,VAN LANSCHOT JJB.Response to the comment on "active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer" ［J］.Ann Surg,2021,274(6):e697-e698.
[38] YU W,YANG X,CHU L,et al.Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients ［J］.Pathol Res Pract,2018,214(7):1017-1023.
[39] MAZORRA Z,CHAO L,LAVASTIDA A,et al.Nimotuzumab:beyond the EGFR signaling cascade inhibition ［J］.Semin Oncol,2018,45(1-2):18-26.
[40] JING W,YAN W,LIU Y,et al.Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma ［J］.Cancer Biol Ther,2019,20(8):1121-1126.
[41] CHEN Y,WU X,HAO D,et al.Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma ［J］.Oncotarget,2018,10(40):4069-4078.
[42] CUNNINGHAM D,STENNING SP,SMYTH EC,et al.Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma(UK Medical Research Council ST03):primary analysis results of a multicentre,open-label,randomised phase 2-3 trial ［J］.Lancet Oncol,2017,18(3):357-370.
[43] RIVERA F,IZQUIERDO-MANUEL M,GARCIA-ALFONSO P,et al.Perioperative trastuzumab,capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma:NEOHX phase II trial ［J］.Eur J Cancer,2021,145:158-167.
[44] YAGI T,BABA Y,ISHIMOTO T,et al.PD-L1 expression,tumor-infiltrating lymphocytes,and clinical outcome in patients with surgically resected esophageal cancer ［J］.Ann Surg,2019,269(3):471-478.
[45] KATOK,CHO BC,TAKAHASHI M,et al.Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy(ATTRACTION-3):a multicentre,randomised,open-label,phase 3 trial ［J］.The Lancet Oncology Vol,2019,20(11):1506-1517.
[46] SUN JM,SHEN L,SHAH MA,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590):a randomised,placebo-controlled,phase 3 study ［J］.Lancet,2021,398(10302):759-771.
[47] KOJIMA T,SHAH MA,MURO K,et al.Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer ［J］.J Clin Oncol,2020,38(35):4138-4148.
[48] JANJIGIAN YY,SHITARA K,MOEHLER M,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma(CheckMate 649):a randomised,open-label,phase 3 trial ［J］.Lancet,2021,398(10294):27-40.
[49] KELLY RJ,AJANI JA,KUZDZAL J,et al.Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer ［J］.N Engl J Med,2021,384(13):1191-1203.
[50] SHEN D,CHEN Q,WU J,et al.The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma ［J］.J Gastrointest Oncol,2021,12(1):1-10.
[51] 宋琪,杨淑莉,郑翠玲,等.卡瑞利珠单抗联合白蛋白紫杉醇/洛铂新辅助治疗局部晚期食管癌疗效和安全性Ⅱ期临床观察［J］.中华转移性肿瘤杂志,2021,04(03):218-222.
SONG Q,YANG SL,ZHENG CL,et al Phase II clinical observation on the efficacy and safety of carelizumab combined with albumin paclitaxel/lobaplatin in the treatment of locally advanced esophageal cancer ［J］.Chinese Journal of Metastatic Tumors,2021,04(03):218-222.
[52] WU Z,ZHENG Q,CHEN H,et al.Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma ［J］.J Thorac Dis,2021,13(6):3518-3528.
[53] LI C,ZHAO S,ZHENG Y,et al.Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma(PALACE-1)［J］.Eur J Cancer,2021,144:232-241.
[54] TEIXEIRA FARINHA H,DIGKLIA A,SCHIZAS D,et al.Immunotherapy for esophageal cancer:state-of-the art in 2021 ［J］.Cancers(Basel),2022,14(3):554.